Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07123103 · ClinicalTrials.gov registry record · Phase 1
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by Exelixis.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 9
- Study locations
NCT07123103: Recruiting Phase 1 study of Solid Tumors, sponsored by Exelixis.
NCT07123103 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by Exelixis. The registered enrollment target is 150 participants, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (47% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07123103, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by Exelixis.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 9
- Study locations
Study Summary
The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.
Conditions Studied
Interventions
- DRUG XB371
Study Locations (9)
Texas
- Exelixis Clinical Site #8 - Houston
- Exelixis Clinical Site #1 - San Antonio
Arkansas
- Exelixis Clinical Site #5 - Rogers
California
- Exelixis Clinical Site #9 - Los Angeles
District of Columbia
- Exelixis Clinical Site #6 - Washington D.C.
Florida
- Exelixis Clinical Site #4 - Orlando
Michigan
- Exelixis Clinical Site #3 - Grand Rapids
New Jersey
- Exelixis Clinical Site #7 - New Brunswick
North Carolina
- Exelixis Clinical Site #2 - Huntersville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2028-02 |
| Phase | Phase 1 |
What NCT07123103 shows while recruiting
NCT07123103 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which XB371 is the first listed.
NCT07123103 lists 9 locations in 8 states (Texas, Arkansas, California).
Frequently Asked Questions
What is clinical trial NCT07123103 about?
NCT07123103 is a clinical study titled "A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors". The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.
What is the current status of trial NCT07123103?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2025-08-18. Estimated completion is 2028-02.
What conditions does trial NCT07123103 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT07123103?
The interventions under investigation include: XB371 (DRUG).
Who is sponsoring clinical trial NCT07123103?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07123103 being conducted?
This trial has 9 study locations across Arkansas, California, District of Columbia, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07123103's enrollment target sits among peer trials
150 39th of 125 higher than 86 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI